TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04905043
Drug: Acalabrutinib
Normalized name: Acalabrutinib
DrugBank: Acalabrutinib (DB11703)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Participants will receive a single oral dose of acalabrutinib 100 mg capsule on Day 1 (Period 1) and Day 4 (Period 2).
Study: NCT04595318
Drug: Standard clinical care first, followed by standard clinical care and varenicline
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard clinical care includes substance use disorder treatment program-based individual behavioral counseling at least once a month using motivational and cognitive behavioral strategies. Varenicline therapy includes a one month's supply of the medication in standard doses: 0.5 mg for 3 days, 0.5 mg twice a day for 4 days, then 1 mg twice a day for 21 days.
Study: NCT04595318
Drug: Standard clinical care and varenicline first, followed by standard clinical care
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard clinical care includes substance use disorder treatment program-based individual behavioral counseling at least once a month using motivational and cognitive behavioral strategies. Varenicline therapy includes a one month's supply of the medication in standard doses: 0.5 mg for 3 days, 0.5 mg twice a day for 4 days, then 1 mg twice a day for 21 days.
Study: NCT01039792
Drug: Methyl B12
Normalized name: Methyl vitamin B12
DrugBank: Mecobalamin (DB03614)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 75 µg/Kg subcutaneously injected once every 3 days
Study: NCT00915590
Drug: IL-1Ra
Normalized name: IL-1RA
DrugBank: Anakinra (DB00026)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 5% custom made topical IL-1Ra 3 times a day in both eyes for a period of 6 weeks
Study: NCT00514007
Drug: OSI-906
Normalized name: OSI-461
DrugBank: OSI-461 (DB05415)
Approvals — FDA: no, EMA: no, PMDA: no
Description: OSI-906 administered orally
Study: NCT03356860
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 80mg/m2 IV weekly from week 1 to week12
Study: NCT03356860
Drug: Epirubicin
Normalized name: Epirubicin
DrugBank: Epirubicin (DB00445)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 90 mg/m2 IV Q 2 weeks from week 14 to week 20
Study: NCT03356860
Drug: Durvalumab
Normalized name: Durvalumab
DrugBank: Durvalumab (DB11714)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Durvalumab 1500 mg IV at week 14 and 18
Study: NCT03469531
Drug: Nimotuzumab
Normalized name: nimotuzumab
DrugBank: Nimotuzumab (DB06192)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients receive nimotuzumab IV over 90 minutes on days 1, 8, 15, 22, 29, 36,43.
Study: NCT03469531
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients undergo cisplatin, 25-40 mg/m2 a week for 4 or 5weeks
Study: NCT00681460
Drug: metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: pills given orally twice up to three times a day, a total daily dosage 1000-2400 mg
Study: NCT01934361
Drug: buparlisib
Normalized name: Buparlisib
DrugBank: Buparlisib (DB11666)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buparlisib administered orally on a continuous daily schedule. Buparlisib is manufactured as 10mg and 50mg hard gelatin capsules.
Study: NCT01934361
Drug: carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carboplatin intravenous infusion will be administered at a dose of AUC 5 in a 21 day cycle (every 3 weeks).
Study: NCT01934361
Drug: lomustine
Normalized name: Lomustine
DrugBank: Lomustine (DB01206)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lomustine will be administered as a single oral dose of 100 mg/m² every 6 weeks in a 42 day cycles.
Study: NCT03545503
Drug: Etomidate
Normalized name: Etomidate
DrugBank: Etomidate (DB00292)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Etomidate will be administered as the sedative for RSI on even days
Study: NCT03545503
Drug: Ketamine
Normalized name: Ketamine
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ketamine will be administered as the sedative for RSI on odd days
Study: NCT02440009
Drug: Itraconazole
Normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral itraconazole 200 mg BD for 6 months
Study: NCT00699894
Drug: aprepitant 40 mg
Normalized name: aprepitant 40 MG
DrugBank: Aprepitant (DB00673)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: aprepitant 40 mg PO 1-3 hours prior to surgery
Study: NCT00699894
Drug: ondansetron 4 mg
Normalized name: ondansetron 4 MG
DrugBank: Ondansetron (DB00904)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ondansetron 4 mg IV 2-5 minutes prior to induction of anesthesia
Study: NCT00297596
Drug: Trastuzumab
Normalized name: trastuzumab
DrugBank: Trastuzumab (DB00072)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Trastuzumab will be administered as an 8 mg/kg loading dose by intravenous (IV) infusion over 90 minutes on day 1 of cycle 1. Subsequent doses will be administered as a 6 mg/kg IV dose over 30 minutes.
Study: NCT00297596
Drug: Oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oxaliplatin will be administered at a dose of 130 mg/ m2 over 120 minutes on day 1 of each cycle, following standard antiemetic premedications. 21 day cycles.~For the first cycle, trastuzumab will be administered before oxaliplatin; however for subsequent cycles, oxaliplatin will be infused prior to trastuzumab
Study: NCT02962960
Drug: Anifrolumab
Normalized name: ANIFROLUMAB
DrugBank: Anifrolumab (DB11976)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: subcutaneous administration every 2 weeks from week 0 to week 50
Study: NCT00638781
Drug: Desmoteplase
Normalized name: Desmoteplase
DrugBank: Desmoteplase (DB04925)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desmoteplase 62.5 µg/kg BW
Study: NCT00638781
Drug: Desmoteplase
Normalized name: Desmoteplase
DrugBank: Desmoteplase (DB04925)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desmoteplase 90 µg/kg BW
Study: NCT00638781
Drug: Desmoteplase
Normalized name: Desmoteplase
DrugBank: Desmoteplase (DB04925)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desmoteplase 125 µg/kg BW
Study: NCT00137709
Drug: Sodium valproate
Normalized name: sodium valproate
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Week 1 \& 2 - 200mg twice daily Week 3 onwards - 400mg twice daily
Study: NCT00137709
Drug: Lamotrigine
Normalized name: Lamotrigine
DrugBank: Lamotrigine (DB00555)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Week 1 - 25mg mane Week 2 - 25mg twice daily Week 3 - 25mg mane, 50mg nocte Week 4 onwards - 50mg twice daily
Study: NCT00231023
Drug: Peribulbar Triamcinolone Acetonide
Normalized name: Triamcinolone Acetonide
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00912301
Drug: Sodium chenodeoxycholate (NaCDC)
Normalized name: chenodeoxycholate
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 500 or 1000 milligrams NaCDC per day each for a period of 4 days
Study: NCT01014234
Drug: Cyclosporins
Normalized name: Cyclosporine
DrugBank: Cyclo(his-pro) (DB02414)
Approvals — FDA: no, EMA: no, PMDA: no
Description: These patients will undergo maintenance immunosuppressive treatment with cyclosporine + mycophenolate + prednisone according to established clinical practice. The dosage of drugs will be based on evaluations of serum trough levels and it will be adjusted when necessary.
Study: NCT01532895
Drug: Hydromorphone HCI OROS
DrugBank: Hydromorphone (DB00327)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: type= exact number, unit= mg, number=4, form= tablet, route= oral use. One tablet administered once a day. The dose may be increased if the level of pain increases or if the pain-killing effect is insufficient.
Study: NCT01014234
Drug: Rapamycin
Normalized name: Rapamycin
DrugBank: Sirolimus (DB00877)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: These patients will undergo maintenance immunosuppressive treatment with rapamycin + mycophenolate + prednisone according to established clinical practice. The dosage of drugs will be based on evaluations of serum trough levels and it will be adjusted when necessary.
Study: NCT04395768
Drug: Hydroxychloroquine
Normalized name: Hydroxychloroquine
DrugBank: Hydroxychloroquine (DB01611)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Active comparator group will receive: a combination of 2 drugs and 3 dietary supplements
Study: NCT01502670
Drug: 18F-FACBC Radiotracer
Normalized name: (18F)FACBC
DrugBank: Fluciclovine (18F) (DB13146)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Test radiotracer uptake in lung nodule
Study: NCT00578903
Drug: Cytoxan
Normalized name: Cytoxan
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cytoxan will be given at 50 mg/kg per dose for 4 successive days.
Study: NCT00578903
Drug: Campath
Normalized name: Campath
DrugBank: Alemtuzumab (DB00087)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Campath will be given at a dose of 3 mg for patients whose weight is between 5 and 15 kg; at a dose of 5 mg for patients whose weight is between 16 and 30 kg; and at a dose of 10 mg for patients whose weight is greater than 30 kg. The last dose of Campath should be 24 hours or more before stem cell infusion.
Study: NCT00578903
Drug: FK-506
Normalized name: FK-960
DrugBank: FK-960 (DB06465)
Approvals — FDA: no, EMA: no, PMDA: no
Description: FK-506 will be given at a dose of 0.03 mg/kg/day via continuous infusion over 24 hours from 4pm on day -2 until engraftment or when patient is able to take by mouth (PO), then 0.03 mg/kg PO every 12 hours.
Study: NCT03022409
Drug: Ceralasertib
Normalized name: Ceralasertib
DrugBank: Ceralasertib (DB14917)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceralasertib is an oral agent and will be dosed at 160 mg. Ceralasertib tablets should be taken at the same time each day, approximately 12 hours apart (maximum ± 2 hour window) with one glass of water.~Ceralasertib is a potent, selective inhibitor of the serine/threonine-specific protein kinase, ataxia telangiectasia and Rad3-related protein (ATR), with good selectivity against other phosphatidylinositol 3-kinase-related kinase (PIKK) family members.
Study: NCT03022409
Drug: Olaparib
Normalized name: Olaparib
DrugBank: Olaparib (DB09074)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Olaparib is available as a green film-coated tablet containing 100 mg or 150 mg of Olaparib. Patients will be administered Olaparib orally twice daily at 300 mg bid. The Olaprib tablets should be taken at the same time each day, approximately 12 hours apart with one glass of water.~Olaparib (AZD2281, KU-0059436) is a potent Polyadenosine 5'diphosphoribose \[poly (ADP ribose)\] polymerisation (PARP) inhibitor (PARP-1, -2 and -3) that is being developed as an oral therapy, both as a monotherapy (including maintenance) and for combination with chemotherapy and other anti-cancer agents.
Study: NCT00003012
Drug: epirubicin hydrochloride
Normalized name: Epirubicin Hydrochloride
DrugBank: Epirubicin (DB00445)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02858401
Drug: Vesatolimod
Normalized name: Vesatolimod
DrugBank: Vesatolimod (DB12687)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet(s) administered orally once every 2 weeks
Study: NCT00614835
Drug: Docetaxel plus Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Gemcitabine 900 mg/m2 IV over 90 minutes day 1 Gemcitabine 900 mg/m2 IV over 90 minutes day 8 + Docetaxel 75 mg/m2 IVPB day 8 Dexamethasone 8 mg po bid days 7-9 GCSF 150 ug/m2 (round to nearest vial size: 350 ug or 480 ug) SQ days 9-15 Repeat every 21 days for total of 4 cycles
Study: NCT02202005
Drug: Nevirapine
Normalized name: Nevirapine
DrugBank: Nevirapine (DB00238)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nevirapine 400mg PR tablet
Study: NCT03864133
Drug: Omidria
Normalized name: Omidria
DrugBank: Phenylephrine (DB00388)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Phenylephrine and Ketorolac infusion of 1%/0.3% during cataract surgery.
Study: NCT02947269
Drug: Prucalopride
Normalized name: PRUCALOPRIDE
DrugBank: Prucalopride (DB06480)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Prucalopride 2mg capsule
Study: NCT05468892
Drug: Panitumumab 20 MG/1 ML Intravenous Solution [VECTIBIX]
Normalized name: Panitumumab 20 MG/1 ML Intravenous Solution [VECTIBIX]
DrugBank: Panitumumab (DB01269)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Panitumumab will be administered as a 6 mg/kg intravenous infusion over 60 minutes every 2 weeks (q2w) of a 28-day cycle (Day 1 and Day 15).
Study: NCT01266681
Drug: amiodarone
Normalized name: Amiodarone
DrugBank: Amiodarone (DB01118)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Visit One:. Once consent is given patarticipants will be randomised into either group and instructed and prescribed the drug as appropriate.~Visit Two: Patients will attend for routine cardioversion. This is performed by an experienced CCU nurse as per normal protocol. Patients will also undergo an ECG, and fill in symptom and quality of life (QoL) questionnaires.~Visit Three: Patients will attend a routine outpatient appointment 6 weeks post cardioversion. They will undergo ECG and fill in symptom and QoL questionnaires~Visit Four: Participants will attend at 12 weeks for ECG, symptom and QoL questionnaires~Visit Five: Participants will attend at 24 weeks for ECG, symptom and QoL questionnaires~Visit Six: Participants will attend at 36 weeks for ECG, symptom and QoL questionnaires~Visit Seven: Participants will attend at 52 weeks for ECG, symptom and QoL questionnaires. Participants will then be followed up as per protocol by their consultant cardiologist.
Study: NCT01266681
Drug: Dronedarone
Normalized name: Dronedarone
DrugBank: Dronedarone (DB04855)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Visit One: patarticipants will be randomised into either group and instructed and prescribed the drug as appropriate.~Visit Two: Patients will attend for routine cardioversion. This is performed by an experienced CCU nurse as per normal protocol. Patients will also undergo an ECG, and fill in symptom and quality of life (QoL) questionnaires.~Visit Three: Patients will attend a routine outpatient appointment 6 weeks post cardioversion. They will undergo ECG and fill in symptom and QoL questionnaires~Visit Four: Participants will attend at 12 weeks for ECG, symptom and QoL questionnaires~Visit Five: Participants will attend at 24 weeks for ECG, symptom and QoL questionnaires~Visit Six: Participants will attend at 36 weeks for ECG, symptom and QoL questionnaires~Visit Seven: Participants will attend at 52 weeks for ECG, symptom and QoL questionnaires. Participants will then be followed up as per protocol by their consultant cardiologist.
Study: NCT01818583
Drug: Potassium chloride
Normalized name: Potassium Chloride
DrugBank: Potassium chloride (DB00761)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02723331
Drug: Nab paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Nab-paclitaxel and gemcitabine, for R-PDAC patients, will be given in combination as neoadjuvant and adjuvant chemotherapy. Nab-paclitaxel will be administered by IV infusion at a dose of 125 mg/m2 over 30 minutes on Days 1, 8, and 15 of every 28-day cycle. Gemcitabine will be administered by IV infusion, immediately after the administration of nab-paclitaxel, at a dose of 1000 mg/m2 over 30 minutes on Days 1, 8 and 15 of every 28-day cycle.
Study: NCT02723331
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Nab-paclitaxel and gemcitabine, for BR-PDAC patients, will be given in combination as neoadjuvant and adjuvant chemotherapy. Nab-paclitaxel will be administered by IV infusion at a dose of 125 mg/m2 over 30 minutes on Days 1, 8, and 15 of every 28-day cycle. Gemcitabine will be administered by IV infusion, immediately after the administration of nab-paclitaxel, at a dose of 1000 mg/m2 over 30 minutes on Days 1, 8 and 15 of every 28-day cycle.
Study: NCT02086604
Drug: Brentuximab vedotin
Normalized name: Brentuximab Vedotin
DrugBank: Brentuximab vedotin (DB08870)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02086604
Drug: Lenalidomide
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00116753
Drug: Degarelix
Normalized name: Degarelix
DrugBank: Degarelix (DB06699)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Drug: Degarelix subcutaneous 240 mg (40 mg/mL) initiation dose, maintenance dose 240 mg (40 mg/mL) at months 1, 3, 6 and 9
Study: NCT00116753
Drug: Degarelix
Normalized name: Degarelix
DrugBank: Degarelix (DB06699)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Drug: Degarelix subcutaneous 240 mg (40 mg/mL) initiation dose, maintenance dose 240 mg (60 mg/mL) at months 1, 3, 6 and 9
Study: NCT00116753
Drug: Degarelix
Normalized name: Degarelix
DrugBank: Degarelix (DB06699)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Drug: Degarelix subcutaneous 240 mg (40 mg/mL) initiation dose, maintenance dose 240 mg (60 mg/mL) at months 1, 4, 7 and 10
Study: NCT01642251
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT01642251
Drug: Etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT01642251
Drug: Veliparib
Normalized name: veliparib
DrugBank: Veliparib (DB07232)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given PO
Study: NCT03776227
Drug: sotagliflozin (SAR439954)
Normalized name: sotagliflozin
DrugBank: Sotagliflozin (DB12713)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Pharmaceutical form: tablet~Route of administration: oral
Study: NCT03520946
Drug: Ramucirumab
Normalized name: Ramucirumab
DrugBank: Ramucirumab (DB05578)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 8 mg/kg iv over 60 min on d1+15, q4w
Study: NCT03520946
Drug: TAS 102
Normalized name: Ta
DrugBank: Tantalum (DB12859)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 35mg/m2 p.o. twice daily (BID) d1-5 and d8-12, q4w
Study: NCT00192114
Drug: Enzastaurin HCl
Normalized name: Chlorpromazine Hydrochloride
DrugBank: Enzastaurin (DB06486)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1200 milligrams (mg) loading dose orally, then 500 mg, orally, daily, up to six 28-day cycles.
Study: NCT00902655
Drug: Desmopressin
Normalized name: Desmopressin
DrugBank: Desmopressin (DB00035)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Desmopressin 0.1,0.2 or 0.4 mg once daily for 3-weeks of dose titration phase and 4-weeks of treatment phase
Study: NCT01792739
Drug: Lactobacillus casei variety rhamnosus granules
Normalized name: Lactobacillus casei rhamnosus
DrugBank: Lactobacillus casei (DB16541)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactobacillus casei variety rhamnosus granules~: 3 gram per day (1g-1g-1g, 3 times per day)
Study: NCT00492297
Drug: Sorafenib (Nexavar, BAY43-9006) + Dacarbazine (DTIC)
Normalized name: sorafenib 200 MG [Nexavar]
DrugBank: Sorafenib (DB00398)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dacarbazine 1000 mg/m\^2 on day one of repeated 21 day cycles, in combination with daily continuous oral sorafenib (Nexavar, BAY 43-9006), 400 mg twice a day (bid)
Study: NCT03541837
Drug: Ropivacaine
Normalized name: Ropivacaine
DrugBank: Ropivacaine (DB00296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ESP catheter
Study: NCT02850484
Drug: Budesonide
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Inhaled corticosteroid
Study: NCT02850484
Drug: Formoterol
Normalized name: Formoterol
DrugBank: Formoterol (DB00983)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Long Acting Beta Agonist (LABA)
Study: NCT02073747
Drug: Albuterol
Normalized name: Albuterol
DrugBank: Albuterol (DB01001)
Approvals — FDA: no, EMA: no, PMDA: no
Description: One hour inhaled ten milligrams of albuterol
Study: NCT01620476
Drug: liraglutide
Normalized name: Liraglutide
DrugBank: Liraglutide (DB06655)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 5 mcg/kg for 21 days. Injected subcutaneously once daily. Progression to the next dose level based on safety data
Study: NCT03064113
Drug: TD-4208 700 μg
Normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03064113
Drug: Ipratropium 500 μg
Normalized name: Ipratropium
DrugBank: Ipratropium (DB00332)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01620476
Drug: liraglutide
Normalized name: Liraglutide
DrugBank: Liraglutide (DB06655)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 5 mcg/kg for 7 days followed by 10 mcg/kg for 14 days. Injected subcutaneously once daily. Progression to the next dose level based on safety data
Study: NCT01620476
Drug: liraglutide
Normalized name: Liraglutide
DrugBank: Liraglutide (DB06655)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 5 mcg/kg for 7 days followed by 10 mcg/kg for 7 days followed by 15 mcg/kg for 7 days. Injected subcutaneously once daily
Study: NCT00178100
Drug: paroxetine
Normalized name: Paroxetine
DrugBank: Paroxetine (DB00715)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00110123
Drug: fotemustine
Normalized name: fotemustine
DrugBank: Fotemustine (DB04106)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03983668
Drug: CMP-001
Normalized name: Cmp-001 component cpg-a oligodeoxynucleotide tlr9 agonist
DrugBank: Vidutolimod (DB17500)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunostimulatory therapeutic agent
Study: NCT03983668
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Humanized antibody used in cancer immunotherapy
Study: NCT02669173
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Drug given by IV, 10 mg/kg days 1, 15 every 28 days, until progression.
Study: NCT00466869
Drug: Betahistine
Normalized name: betahistine
DrugBank: Betahistine (DB06698)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04596488
Drug: Efavirenz 400mg
Normalized name: EFAVIRENZ 400MG/LAMIVUDINE 300MG/TENOFOVIR DF 300MG TAB
DrugBank: Efavirenz (DB00625)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: HIV-infected patients were treated with efavirenz 400mg combined with tenofovir 300mg and lamivudine 300mg.
Study: NCT00506844
Drug: Cetuximab, Irinotecan, Capecitabine
DrugBank: Cetuximab (DB00002)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT02305836
Drug: donepezil
Normalized name: Donepezil
DrugBank: Donepezil (DB00843)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: cholinesterase inhibitors (ChE-Is)
Study: NCT02824419
Drug: DOTANOC
Normalized name: 68-ga-dotanoc
DrugBank: Dotatoc gallium Ga-68 (DB18190)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subject undergoes imaging studies with FDG and with DOTANOC.
Study: NCT00398554
Drug: etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 150 mg/m²/day, 2 hours i.v.infusion (intravenous drip) on days 1 - 3
Study: NCT00398554
Drug: prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 40 mg/m2/day p.o. (intake by mouth)divided in 3 single doses daily from day 1 - 14 and day 21 - 34